Pathology: es-BC - HER2 negative - (neo)adjuvant (NA);
es-BC - HER2 negative - (neo)adjuvant (NA) | ||
I-SPY2, 2020 | ||
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide | 1 | T1 |
paclitaxel followed by doxorubicin plus cyclophosphamide | 0 | T0 |